Drug name - Calquence

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7459554 ASTRAZENECA Imidazopyrazine tyrosine kinase inhibitors
Nov, 2026

(4 years from now)

US9290504 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(9 years from now)

US9796721 ASTRAZENECA Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
Jul, 2036

(13 years from now)

CN1898240B ASTRAZENECA Imidazole And Pyrazine Type Tyrosine Kinase Inhibitor
Dec, 2014

(7 years ago)

CN1898240A ASTRAZENECA Imidazopyrazine Tyrosine Kinase Inhibitors
Dec, 2014

(7 years ago)

CN103889987A ASTRAZENECA As An Inhibitor Of Btk-4-Imidazole And -1--- Benzamide And 4 - - Imidazo Triazine -1--- Benzamide
Jul, 2032

(9 years from now)

CN106243113A ASTRAZENECA Imidazole As Selective Btk Inhibitors And Paradiazine
Jul, 2032

(9 years from now)

CN103889987B ASTRAZENECA Imidazole As Selective Btk Inhibitors And Paradiazine
Jul, 2032

(9 years from now)

CN106243113B ASTRAZENECA As A Selective Btk Inhibitor And Pyrazine
Jul, 2032

(9 years from now)

CN108349978B ASTRAZENECA Solid Forms And Formulations Of (S) -4-(8-Amino - -3-(1 - (But - -2 - Yn-Yl) - Pyrrolidin - -2 - Yl) Imidazo [1, 5-A] Pyrazin-1-Yl) -N-(Pyridine-2-Yl) Benzamide
Jul, 2036

(13 years from now)

CN108349978A ASTRAZENECA (S) -4-(8-Amino - -3-(1 - (But - -2 - Alkyne Acyl) - Pyrrolidin - -2 - Yl) Imidazo [1, 5-A] Pyrazin - -1 - Yl) - N - (Pyridine - -2 - Yl) Benzamide In Solid Form And Preparation
Jul, 2036

(13 years from now)

IN200601290P4 ASTRAZENECA Imidazopyrazine Tyrosine Kinase Inhibitors
Oct, 2024

(2 years from now)

IN249666B ASTRAZENECA Imidazopyrazine Tyrosine Kinase Inhibitors
Oct, 2024

(2 years from now)

EP1675860B1 ASTRAZENECA Imidazo[1,5-A]Pyrazines As Tyrosine Kinase Inhibitors
Oct, 2024

(2 years from now)

EP1675860A2 ASTRAZENECA Imidazo[1,5-A]Pyrazines As Tyrosine Kinase Inhibitors
Oct, 2024

(2 years from now)

EP3689878B1 ASTRAZENECA 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors
Jul, 2032

(9 years from now)

EP3689878A1 ASTRAZENECA 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors
Jul, 2032

(9 years from now)

EP2734522B1 ASTRAZENECA 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors
Jul, 2032

(9 years from now)

EP2734522A1 ASTRAZENECA 4-Imidazopyridazin-1-Yl-Benzamides And 4-Imidazotriazin-1-Yl-Benzamides As Btk-Inhibitors
Jul, 2032

(9 years from now)

EP3317281A1 ASTRAZENECA Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide
Jul, 2036

(13 years from now)

EP3613745B1 ASTRAZENECA Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide
Jul, 2036

(13 years from now)

EP3317281B1 ASTRAZENECA Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide
Jul, 2036

(13 years from now)

EP3613745A1 ASTRAZENECA Solid Forms And Formulations Of (S)-4-(8-Amino-3-(1-(But-2-Ynoyl)Pyrrolidin-2-Yl)Imidazo[1,5-A]Pyrazin-1-Yl)-N-(Pyridin-2-Yl)Benzamide
Jul, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10239883 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors Jul, 2032

(9 years from now)

US9758524 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors Jul, 2032

(9 years from now)

US10272083 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor Jan, 2035

(12 years from now)

US10167291 ASTRAZENECA Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide Jul, 2036

(13 years from now)

Drugs and Companies using ACALABRUTINIB ingredient

Treatment: Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; treatment of adult patients with chronic lymphocytic leukemia; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy by administering 100 mg of acalabrutinib twice daily; treatment of adult patients with small lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily; treatment of adult patients with previously untreated chronic lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab by administering 100 mg of acalabrutinib twice daily; treatment of adult patients with chronic lymphocytic leukemia by administering 100mg of acalabrutinib twice daily; treatment of adult patients with previously untreated small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab; Treatment of adult patients with small lymphocytic leukemia; treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia; treatment of adult patients with chronic lymphocytic leukemia; treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; treatment of adult patients with previously untreated small lymphocytic leukemia in combination with obinutuzumab; treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab; treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
100MG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.